Drug Information

Drug (ID: DG01702) and It's Reported Resistant Information

• Name: Panitumumab/Trametinib
• Synonyms: Panitumumab/Trametinib
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Colorectal cancer [ICD-11: 2B91]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: MAPK/ERK kinase 1 (MEK1) [1]

• Molecule Alteration: Missense mutation; p.K57N (c.171G>C)
• Sensitive Disease: Colorectal cancer [ICD-11: 2B91.1]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: HCA46 cells; Colon; Homo sapiens (Human); CVCL_2468
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: CellTiter-Glo assay

Key Molecule: MAPK/ERK kinase 1 (MEK1) [1]

• Molecule Alteration: Missense mutation; p.K57T (c.170A>C)
• Sensitive Disease: Colorectal cancer [ICD-11: 2B91.1]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: HCA46 cells; Colon; Homo sapiens (Human); CVCL_2468
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: CellTiter-Glo assay

Key Molecule: MAPK/ERK kinase 1 (MEK1) [1]

• Molecule Alteration: Missense mutation; p.K57T (c.170A>C)
• Sensitive Disease: Colorectal cancer [ICD-11: 2B91.1]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: HCA46 cells; Colon; Homo sapiens (Human); CVCL_2468
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: CellTiter-Glo assay

References

• Ref 1: Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal CancerCancer Discov. 2016 Feb;6(2):147-153. doi: 10.1158/2159-8290.CD-15-1283. Epub 2015 Dec 7.